Alzheimer’s Disease (AD) is a major global health challenge. It is a complex neurodegenerative disorder. Effective and affordable treatments are urgently needed. This article highlights key drugs in development and focuses on Phase II and III trials in 2025. It reviews their mechanisms, progress, and market potential. Market Boom: AD Therapeutics to Hit $17B by … The 2025 Alzheimer’s Drug Pipeline: Market Projections and Clinical Breakthroughs Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.